Physician profile
Michael S Morelli
NPI 1760489942
$5,129.87
in general payments reported to CMS, 2019-2025
31 companies · $745 in 2025
The $745 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $351 · 2021: $951 · 2022: $810 · 2023: $838 · 2024: $985 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.01 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,788.83 | 2019-2025 | |
| Janssen Biotech, INC. | $413.08 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Daiichi Sankyo INC. | $338.80 | 2023-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.35 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $238.48 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $185.16 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.22 | 2019-2024 | Entyvio, Eohilia |
| Pfizer INC. | $119.97 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $83.90 | 2020-2023 | Linzess |
| Merck Sharp & Dohme LLC | $56.13 | 2022-2024 | Dificid |
| Ucb, INC. | $48.74 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $47.76 | 2024 | |
| Mallinckrodt Hospital Products INC. | $33.62 | 2025 | Terlivaz |
| Redhill Biopharma INC. | $32.82 | 2020-2022 | |
| Laborie Medical Technologies Corp. | $27.52 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.45 | 2024 | |
| Novo Nordisk INC | $23.11 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $20.71 | 2024 | |
| Ardelyx, INC. | $19.97 | 2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $18.70 | 2021 | |
| Shield Therapeutics INC | $18.10 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $17.50 | 2024 | Blueboost |
| Alexion Pharmaceuticals, INC. | $16.88 | 2019 | |
| Shire North American Group INC | $16.87 | 2019 | |
| Sandoz INC. | $16.81 | 2024 | Hyrimoz |
| Phathom Pharmaceuticals, INC. | $16.43 | 2024 | Voquezna |
| Amgen INC. | $15.78 | 2024 | |
| Qol Medical, LLC | $15.74 | 2019 | |
| Braintree Laboratories, INC. | $14.28 | 2019 | |
| Allergan, INC. | $11.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$21,955.68 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.